Periodic paralysis: Difference between revisions

From WikiMD's Wellness Encyclopedia

No edit summary
No edit summary
Line 1: Line 1:
{{short description|Human genetic disease}}
{{short description|Human genetic disease causing episodes of muscle weakness or paralysis}}
{{Infobox medical condition (new)
{{Infobox medical condition
| name            = Periodic paralysis
| name            = Periodic paralysis
| image          =
| synonyms       = '''Myoplegia paroxysmalis familiaris'''
| caption        =
| field          = [[Neurology]], [[Medical genetics]]
| synonyms       ='''Myoplegia paroxysmalis familiaris'''
| complications  = [[Respiratory failure]], [[cardiac arrhythmia]]
| complications  =  
| onset          = Typically childhood or adolescence
| onset          =  
| duration        = Lifelong
| duration        =  
| types          = [[Hypokalemic periodic paralysis]], [[Hyperkalemic periodic paralysis]], [[Paramyotonia congenita]], [[Andersen–Tawil syndrome]]
| types          =  
| causes          = [[Genetic mutation]]s affecting [[ion channels]]
| causes          =  
| risks          = Family history, exercise, carbohydrate-rich meals, stress
| risks          =  
| diagnosis      = [[Genetic testing]], [[electromyography]], [[blood test]]s for potassium
| diagnosis      =  
| differential    = [[Myasthenia gravis]], [[thyrotoxic periodic paralysis]], [[Guillain–Barré syndrome]]
| differential    =  
| prevention      = Avoidance of triggers (e.g. high-carb meals, strenuous activity)
| prevention      =  
| treatment      = Lifestyle modification, [[potassium supplements]], [[carbonic anhydrase inhibitors]]
| treatment      =  
| medication      = [[Acetazolamide]], [[dichlorphenamide]], potassium chloride
| medication      =  
| prognosis      = Variable; symptoms may be controlled with appropriate management
| prognosis      =  
| frequency      = Rare
| frequency      =  
| deaths          = Rare, may occur with severe cardiac involvement
| deaths          =  
}}
}}
'''Periodic paralysis''' is a group of rare [[genetic disease]]s that lead to weakness or paralysis <ref>{{Cite journal|date=2017-01-07|title=Periodic Paralyses: Background, Pathophysiology, Epidemiology|url=http://emedicine.medscape.com/article/1171678-overview}}</ref> from common triggers such as cold, heat, high [[carbohydrate]] meals, not eating, stress or excitement and physical activity of any kind. The underlying mechanism of these diseases are malfunctions in the [[ion channel]]s in [[skeletal muscle]] [[cell membrane]]s that allow electrically charged ions to leak in or out of the muscle cell, causing the cell to depolarize and become unable to move.<ref>{{Cite journal|date=2017-01-07|title=Periodic Paralyses: Background, Pathophysiology, Epidemiology|url=http://emedicine.medscape.com/article/1171678-overview}}</ref>
'''Periodic paralysis''' is a group of rare [[genetic disorder]]s characterized by recurring episodes of muscle weakness or [[paralysis]]. These episodes are often associated with abnormal levels of [[potassium]] in the blood, although some cases show normal potassium levels during attacks. Periodic paralysis is considered a form of [[channelopathy]]—a disorder caused by dysfunctional [[ion channel]]s in muscle cell membranes.


The symptoms of periodic paralysis can also be caused by [[hyperthyroidism]], and are then labeled [[thyrotoxic periodic paralysis]]; however, if this is the underlying condition there are likely to be other characteristic manifestations, enabling a correct diagnosis.
Although primarily genetic, a similar condition known as '''[[thyrotoxic periodic paralysis]]''' may occur in individuals with [[hyperthyroidism]], particularly in people of Asian or Latin American descent.


==Types==
== Types ==
Periodic paralysis is an [[autosomal dominant]] [[myopathy]] with considerable variation in [[penetrance]], leading to a spectrum of familial [[phenotype]]s (only one parent needs to carry the gene mutation to affect the children, but not all family members who share the gene are affected to the same degree). Specific diseases include:
Periodic paralysis disorders are typically inherited in an [[autosomal dominant]] fashion and can vary widely in expression and severity among individuals. The major forms include:


* [[Hypokalemic periodic paralysis]] ({{OMIM|170400}}), where potassium leaks into the muscle cells from the bloodstream.
=== Hypokalemic periodic paralysis ===
* [[Hyperkalemic periodic paralysis]] ({{OMIM|170500}}), where potassium leaks out of the cells into the bloodstream.
*Caused by mutations in the [[CACNA1S]] or [[SCN4A]] gene.
* [[Paramyotonia congenita]] ({{OMIM|168300}}), a form which often accompanies hyperkalemic periodic paralysis, but may present alone. The primary symptom of paramyotonia congenita is muscle contracture which develops during exercise or activity. Paramyotonia congenita attacks may also be triggered by a low level of potassium in the bloodstream. This means people with both hyperkalemic periodic paralysis and paramyotonia congenita can have attacks with fluctuations of potassium up or down.
*Episodes are triggered by a drop in blood potassium levels, often after exercise or high-carbohydrate meals.
* [[Andersen-Tawil syndrome]] ({{OMIM|170390}}), a form of periodic paralysis that includes significant heart rhythm problems, fainting and risk of sudden death. Potassium levels may be low, high, or normal during attacks of ATS. Patients with ATS may also have skeletal abnormalities like [[scoliosis]] (curvature of the spine), webbing between the second and third toes or fingers ([[syndactyly]]), crooked fingers (clinodactyly), a small jaw ([[micrognathia]]) and low-set ears.  Patients need to have another form of periodic paralysis to have the Andersen-Tawil.  If a patient has hypo or hyper periodic paralysis they have a 50% chance of getting Andersen-Tawil.  They just have to have the gene that causes it. This is a rare occurrence of having this.  Only around 100 people in the world are recorded to have it.
*Common symptoms include weakness in the limbs, typically occurring upon waking or after rest.
==Cause==
One of the most common descriptions of periodic paralysis are episodic attacks of muscle weakness, which are commonly associated with serum potassium levels. Physical activity and diet content (carbohydrates) have been identified as PP triggers. Unlike non-dystrophic myotonias, the periodic paralysis phenotype is triggered after resting following exercise. Voltage-gated sodium channel (Nav1.4) mutations are among the key causes behind periodic paralysis.<ref name=pmid29674667>{{cite journal | vauthors = Ghovanloo MR, Abdelsayed M, Peters CH, Ruben PC | title = A Mixed Periodic Paralysis & Myotonia Mutant, P1158S, Imparts pH-Sensitivity in Skeletal Muscle Voltage-gated Sodium Channels | journal = Scientific Reports | volume = 8 | issue = 1 | pages = 13 | date = 2018 | pmid = 29674667 | pmc = 5908869 | doi = 10.1038/s41598-018-24719-y | bibcode = 2018NatSR...8.6304G }}</ref>


Hyper-kalemic PP (hyperPP) is identified with high extracellular potassium levels which are typically greater than 5 mM during attacks; however, HyperPP attacks can also take place without rise in potassium concentrations. HyperPP has a prevalence rate of 1/100,000. Patients become symptomatic around the age of 10. The weakness attacks in hyperPP are relatively short lasting, and range from minutes to hours. The attacks can happen upwards of ten times per month.
=== Hyperkalemic periodic paralysis ===
*Caused by mutations in the [[SCN4A]] gene.
*Characterized by episodes triggered by elevated potassium levels or fasting.
*Muscle stiffness ([[myotonia]]) may accompany episodes, and attacks tend to be shorter than those of the hypokalemic form.


Hypo-kalemic PP (hypoPP) is associated with low potassium levels. The onset of hypoPP occurs between the ages of 15 and 35. The prevalence of hypoPP is estimated to 1/100,000. HypoPP can be triggered by many external factors such as stress, high-sugar diet, and rest after exercise. During hypoPP attacks, the serum potassium concentrations can drop to less than 3 mM. Furthermore, hypoPP attacks are considerably longer lasting than hyperPP. As exercise is a trigger for periodic paralysis attacks, recently there is more research going into the physiological changes that accompany exercise including changes in blood pH. <ref name=pmid29674667>{{cite journal | vauthors = Ghovanloo MR, Abdelsayed M, Peters CH, Ruben PC | title = A Mixed Periodic Paralysis & Myotonia Mutant, P1158S, Imparts pH-Sensitivity in Skeletal Muscle Voltage-gated Sodium Channels | journal = Scientific Reports | volume = 8 | issue = 1 | pages = 13 | date = 2018 | pmid = 29674667 | pmc = 5908869 | doi = 10.1038/s41598-018-24719-y | bibcode = 2018NatSR...8.6304G }}</ref>
=== Paramyotonia congenita ===
*A related condition often co-occurring with hyperkalemic periodic paralysis.
*Characterized by muscle stiffness and weakness triggered by cold exposure or exercise.
*Unlike the other types, symptoms may worsen during activity.


== Diagnosis ==
=== Andersen–Tawil syndrome ===
This disease is unusually difficult to diagnose. Patients often report years of wrong diagnosis and treatments that made them worse instead of better. Part of this may be that [[migraines]] are present in up to 50% of patients and can cause a confusing array of symptoms including headaches, speech difficulties and visual, auditory or sensory auras. [[DNA testing]] is available for only a half dozen common gene mutations, while dozens of known mutations are possible but are not routinely tested. Electromyography (EMG) findings are not specific but the McManis Protocol, also called the Compound Muscle Amplitude Potential test (CMAP) can be used by a skilled neurologist capable of utilizing the EMG, which can give assistance in diagnosing several of these PP disorders. The old glucose/insulin provocative testing can cause life-threatening symptoms and should not be used.
*A rare and complex form of periodic paralysis caused by mutations in the [[KCNJ2]] gene.
*Features include periodic paralysis, [[cardiac arrhythmias]], and distinctive physical characteristics such as:
** [[Scoliosis]]
** [[Clinodactyly]]
** [[Syndactyly]]
** [[Micrognathia]]
** Low-set ears
*Potassium levels can be low, high, or normal during episodes.
*Estimated to affect fewer than 100 individuals globally.
 
== Signs and symptoms ==
Symptoms vary depending on the type but generally include:
 
* Sudden muscle weakness or paralysis lasting from minutes to hours
* Muscle stiffness or [[myotonia]]
* Triggering by rest after exercise, high-carb meals, cold exposure, or stress
* In some cases, difficulty breathing or heart rhythm abnormalities during severe attacks
 
== Cause ==
Periodic paralysis is most often caused by mutations in genes that encode ion channels, especially those involving sodium (Na⁺), calcium (Ca²⁺), and potassium (K⁺) regulation:
 
* Mutations in the **SCN4A** gene affect sodium channels in skeletal muscle.
* Mutations in the **CACNA1S** gene affect calcium channels.
* Mutations in the **KCNJ2** gene affect potassium channels, as seen in Andersen–Tawil syndrome.
 
These mutations disrupt the normal flow of ions into and out of muscle cells, impairing their ability to contract and relax properly.


Also of note is that potassium levels do ''not'' have to range outside of normal limits to cause serious, even life-threatening paralysis. These diseases are ''not'' the same as having a very low level of potassium ([[hypokalemia]]) or high potassium ([[hyperkalemia]]) and must not be treated as such. The total body store of potassium is usually normal; it is just in the wrong place.
== Triggers ==
Common triggers for periodic paralysis episodes include:


== Treatment ==
* Carbohydrate-rich meals
Treatment of the periodic paralyses may include [[carbonic anhydrase]] inhibitors (such as [[acetazolamide]], methazolamide or [[dichlorphenamide]]), taking supplemental oral [[potassium chloride]] and a [[potassium-sparing diuretic]] (for hypos) or avoiding potassium (for hypers), [[thiazide]] [[diuretics]] to increase the amount of potassium excreted by the kidneys (for hypers), and significant lifestyle changes including tightly controlled levels of exercise or activity.  However, treatment should be tailored to the particular type of periodic paralysis.<ref>{{cite journal|last=Kim|first=SJ|author2=Lee, YJ |author3=Kim, JB |title=Reduced expression and abnormal localization of the KATP channel subunit SUR2A in patients with familial hypokalemic periodic paralysis|journal=Biochemical and Biophysical Research Communications|date=Jan 2010|volume=391|issue=1|pages=974–8|doi=10.1016/j.bbrc.2009.11.177|pmid=19962959}}</ref><ref>{{cite journal|last=Kim|first=JB|author2=Kim, MH|title=The Genotype and Clinical Phenotype of Korean Patients with Familial Hypokalemic Periodic Paralysis|journal=J Korean Med Sci|date=Dec 2007|volume=22|issue=6|pages=946–51|doi=10.3346/jkms.2007.22.6.946|pmid=18162704|pmc=2694642}}</ref><ref>{{cite journal|last=Lee|first=GM|author2=Kim JB|title=Hyperkalemic periodic paralysis and paramyotonia congenita caused by a de novo mutation in the SCN4A gene|journal=Neurology Asia|date=June 2011|volume=16|issue=2|pages=163–6}}</ref>
* Fasting
* Rest after strenuous exercise
* Emotional stress
* Cold temperatures
* Certain medications (e.g., [[glucocorticoids]], [[beta-adrenergic agonists]])


Treatment of periodic paralysis in Andersen-Tawil syndrome is similar to that for other types. However, [[Artificial pacemaker|pacemaker]] insertion or an [[implantable cardioverter-defibrillator]] may be required to control cardiac symptoms.<ref>{{cite journal|last=Kim|first=JB|author2=Chung, KW|title=Novel de novo Mutation in the KCNJ2 gene in a Patient with Andersen-Tawil Syndrome|journal=Pediatric Neurology|date=Dec 2009|volume=41|issue=6|pages=464–466|doi=10.1016/j.pediatrneurol.2009.07.010|pmid=19931173}}</ref>
== Diagnosis ==
Diagnosis is typically based on:


== Prognosis ==
* **Clinical history** of episodic muscle weakness or paralysis
While the disability can range from minor, occasional weakness to permanent muscle damage, inability to hold a normal job and use of a powerchair, most people function fairly well with drugs and lifestyle changes.
* **Serum potassium measurement** during an attack
* **Electromyography (EMG)** testing to assess muscle response
* **Genetic testing** to identify causative mutations
* **Provocative testing**, such as glucose-potassium challenge, may be used in specialized centers


== References ==
== Treatment ==
{{Reflist}}
Management focuses on prevention and acute treatment of attacks:


* {{cite journal|last=Song|first=YW|author2=Kim, SJ |author3=Heo, TH |author4=Kim, MH |author5= Kim, JB |title=Normokalemic periodic paralysis is not a distinct disease|journal=Muscle & Nerve|date= Dec 2012|volume=46|issue=6|pages=908–913|doi=10.1002/mus.23441|pmid=22926674}}
=== Preventive measures ===
* Avoidance of triggers (e.g. certain foods, extreme temperatures)
* Low-carbohydrate diet
* Regular, moderate exercise


== External links ==
=== Medications ===
{{Medical resources
* **Potassium chloride** (oral or IV) for hypokalemic attacks
|  DiseasesDB    =
* **Carbonic anhydrase inhibitors** (e.g., [[acetazolamide]], [[dichlorphenamide]]) may help reduce attack frequency
|  ICD10          = {{ICD10|G|72|3|g|70}}
* **Beta-blockers** in some cases of thyrotoxic periodic paralysis
|  ICD9          = {{ICD9|359.3}}
|  ICDO          =
|  OMIM          =
|  MedlinePlus    =
|  eMedicineSubj  =
|  eMedicineTopic =
|  MeshID        = D010245
|  Orphanet      = 206976
}}


*[http://www.ninds.nih.gov/disorders/periodic_paralysis/periodic_paralysis.htm NIH information page on periodic paralysis]
=== Acute management ===
* Careful administration of potassium (oral or IV) or glucose depending on potassium levels
* Close monitoring of cardiac and respiratory function during severe attacks


== Prognosis ==
With appropriate management, many individuals can reduce the frequency and severity of attacks. However, in some cases, long-term muscle weakness (permanent myopathy) may develop. Patients with cardiac involvement, especially in Andersen–Tawil syndrome, require ongoing monitoring and treatment due to risk of serious arrhythmias.


== See also ==
* [[Channelopathy]]
* [[Myopathy]]
* [[Thyrotoxic periodic paralysis]]
* [[Muscle weakness]]
* [[Andersen–Tawil syndrome]]
* [[Potassium]]


== External links ==
* [https://rarediseases.info.nih.gov/diseases/7637/periodic-paralysis Periodic Paralysis – Genetic and Rare Diseases Information Center (GARD)]
* [https://www.periodicparalysis.org Periodic Paralysis International]
{{Muscular Dystrophy}}
{{Muscular Dystrophy}}
{{Diseases of myoneural junction and muscle}}
{{Diseases of myoneural junction and muscle}}
 
{{nt}}
[[Category:Myoneural junction and neuromuscular diseases]]
[[Category:Myoneural junction and neuromuscular diseases]]
[[Category:Channelopathies|Periodic Paralysis]]
[[Category:Channelopathies|Periodic Paralysis]]
[[Category:Rare diseases]]
[[Category:Rare diseases]]
{{No image}}

Revision as of 03:39, 30 March 2025

Human genetic disease causing episodes of muscle weakness or paralysis


Periodic paralysis
Synonyms Myoplegia paroxysmalis familiaris
Pronounce N/A
Specialty N/A
Symptoms N/A
Complications Respiratory failure, cardiac arrhythmia
Onset Typically childhood or adolescence
Duration Lifelong
Types Hypokalemic periodic paralysis, Hyperkalemic periodic paralysis, Paramyotonia congenita, Andersen–Tawil syndrome
Causes Genetic mutations affecting ion channels
Risks Family history, exercise, carbohydrate-rich meals, stress
Diagnosis Genetic testing, electromyography, blood tests for potassium
Differential diagnosis Myasthenia gravis, thyrotoxic periodic paralysis, Guillain–Barré syndrome
Prevention Avoidance of triggers (e.g. high-carb meals, strenuous activity)
Treatment Lifestyle modification, potassium supplements, carbonic anhydrase inhibitors
Medication Acetazolamide, dichlorphenamide, potassium chloride
Prognosis Variable; symptoms may be controlled with appropriate management
Frequency Rare
Deaths Rare, may occur with severe cardiac involvement


Periodic paralysis is a group of rare genetic disorders characterized by recurring episodes of muscle weakness or paralysis. These episodes are often associated with abnormal levels of potassium in the blood, although some cases show normal potassium levels during attacks. Periodic paralysis is considered a form of channelopathy—a disorder caused by dysfunctional ion channels in muscle cell membranes.

Although primarily genetic, a similar condition known as thyrotoxic periodic paralysis may occur in individuals with hyperthyroidism, particularly in people of Asian or Latin American descent.

Types

Periodic paralysis disorders are typically inherited in an autosomal dominant fashion and can vary widely in expression and severity among individuals. The major forms include:

Hypokalemic periodic paralysis

  • Caused by mutations in the CACNA1S or SCN4A gene.
  • Episodes are triggered by a drop in blood potassium levels, often after exercise or high-carbohydrate meals.
  • Common symptoms include weakness in the limbs, typically occurring upon waking or after rest.

Hyperkalemic periodic paralysis

  • Caused by mutations in the SCN4A gene.
  • Characterized by episodes triggered by elevated potassium levels or fasting.
  • Muscle stiffness (myotonia) may accompany episodes, and attacks tend to be shorter than those of the hypokalemic form.

Paramyotonia congenita

  • A related condition often co-occurring with hyperkalemic periodic paralysis.
  • Characterized by muscle stiffness and weakness triggered by cold exposure or exercise.
  • Unlike the other types, symptoms may worsen during activity.

Andersen–Tawil syndrome

  • A rare and complex form of periodic paralysis caused by mutations in the KCNJ2 gene.
  • Features include periodic paralysis, cardiac arrhythmias, and distinctive physical characteristics such as:
  • Potassium levels can be low, high, or normal during episodes.
  • Estimated to affect fewer than 100 individuals globally.

Signs and symptoms

Symptoms vary depending on the type but generally include:

  • Sudden muscle weakness or paralysis lasting from minutes to hours
  • Muscle stiffness or myotonia
  • Triggering by rest after exercise, high-carb meals, cold exposure, or stress
  • In some cases, difficulty breathing or heart rhythm abnormalities during severe attacks

Cause

Periodic paralysis is most often caused by mutations in genes that encode ion channels, especially those involving sodium (Na⁺), calcium (Ca²⁺), and potassium (K⁺) regulation:

  • Mutations in the **SCN4A** gene affect sodium channels in skeletal muscle.
  • Mutations in the **CACNA1S** gene affect calcium channels.
  • Mutations in the **KCNJ2** gene affect potassium channels, as seen in Andersen–Tawil syndrome.

These mutations disrupt the normal flow of ions into and out of muscle cells, impairing their ability to contract and relax properly.

Triggers

Common triggers for periodic paralysis episodes include:

Diagnosis

Diagnosis is typically based on:

  • **Clinical history** of episodic muscle weakness or paralysis
  • **Serum potassium measurement** during an attack
  • **Electromyography (EMG)** testing to assess muscle response
  • **Genetic testing** to identify causative mutations
  • **Provocative testing**, such as glucose-potassium challenge, may be used in specialized centers

Treatment

Management focuses on prevention and acute treatment of attacks:

Preventive measures

  • Avoidance of triggers (e.g. certain foods, extreme temperatures)
  • Low-carbohydrate diet
  • Regular, moderate exercise

Medications

  • **Potassium chloride** (oral or IV) for hypokalemic attacks
  • **Carbonic anhydrase inhibitors** (e.g., acetazolamide, dichlorphenamide) may help reduce attack frequency
  • **Beta-blockers** in some cases of thyrotoxic periodic paralysis

Acute management

  • Careful administration of potassium (oral or IV) or glucose depending on potassium levels
  • Close monitoring of cardiac and respiratory function during severe attacks

Prognosis

With appropriate management, many individuals can reduce the frequency and severity of attacks. However, in some cases, long-term muscle weakness (permanent myopathy) may develop. Patients with cardiac involvement, especially in Andersen–Tawil syndrome, require ongoing monitoring and treatment due to risk of serious arrhythmias.

See also

External links